RT Journal Article
SR Electronic
T1 MTXPK.org: A clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.08.20056713
DO 10.1101/2020.04.08.20056713
A1 Taylor, Zachary L.
A1 Mizuno, Tomoyuki
A1 Punt, Nieko C.
A1 Baskaran, Balaji
A1 Sainz, Adriana Navarro
A1 Shuman, William
A1 Felicelli, Nicholas
A1 Vinks, Alexander A.
A1 Heldrup, Jesper
A1 Ramsey, Laura B.
YR 2020
UL http://medrxiv.org/content/early/2020/04/11/2020.04.08.20056713.abstract
AB Methotrexate (MTX), an anti-folate, is administered at high-doses to treat malignancies in children and adults. However, there is considerable interpatient variability in clearance of high-dose (HD) MTX. Patients with delayed clearance are at an increased risk for severe nephrotoxicity and life-threatening systemic MTX exposure. Glucarpidase is a rescue agent for severe MTX toxicity that reduces plasma MTX levels via hydrolysis of MTX into inactive metabolites, but is only indicated when MTX concentrations are > 2 standard deviations above the mean excretion curve specific for the given dose together with a significant creatinine increase (> 50%). Appropriate administration of glucarpidase is challenging due to the ambiguity in the labeled indication. A recent consensus guideline was published with an algorithm to provide clarity in when to administer glucarpidase, yet clinical interpretation of lab results that do not directly correspond to the algorithm prove to be a limitation of its use.The goal of our study was to develop a clinical decision support tool to optimize the administration of glucarpidase for patients receiving HD MTX. Here, we describe the development of a novel three-compartment MTX population PK model using 31,672 MTX plasma concentrations from 772 pediatric patients receiving HD MTX for the treatment of acute lymphoblastic leukemia and its integration into the online clinical decision support tool, MTXPK.org. This web-based tool has the functionality to utilize individualized demographics, serum creatinine, and real-time drug concentrations to predict the elimination profile and facilitate model-informed administration of glucarpidase.Competing Interest StatementLBR and TM received research funding from BTG, International. NP is president of Medimatics, a company that provides consulting services on medical information systems located in Maastricht, The Netherlands All other authors declared no competing interests for this work Funding StatementThe development of the MTXPK.org webtool was supported by an unrestricted educational grant from BTG, International.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be available upon request